South Korean government decides not to punish interns who resign
South Korea's Minister of Health and Welfare Cho Kyu-hong said at a press conference on the 8th local time that after comprehensively considering the suggestions of frontline interns and the situation on the front line of medical care, the government decided that from that day on, all interns and residents who resigned would not be given administrative sanctions such as revoking their medical licenses.
Cho Kyu-hong also said that for interns and residents who have returned to work and those who have resigned and are preparing to re-register for internship courses in September, the government will make special cases to try to minimize the internship gap and not affect the relevant doctors from obtaining specialist medical licenses.
Cho Kyu-hong said that the government believes that in order to minimize the diagnosis and treatment gaps for critically ill and emergency patients and ensure the smooth training process of interns and residents, it is in the public interest, so it has made a decision not to punish interns and residents who resigned. It is hoped that major hospitals will complete the resignation processing of doctors who have not returned to work before July 15 and determine the scale of vacancies. Previously, large general hospitals in South Korea, such as Seoul National University Hospital, Yonsei University Severance Hospital, and Seoul Asan Medical Center, suspended or limited their medical services in an effort to cancel all penalties against interns and residents.
iPhone 16 Pro leak just confirmed a huge camera upgrade
The tetraprism lens with 5x optical zoom currently exclusive to the iPhone 15 Pro Max could be headed to both the iPhone 16 Pro and iPhone 16 Pro Max, narrowing the gap between Apple's premium flagships. That's according to a new report from analyst Ming-Chi Kuo, who cites a recent earnings call with Apple lens supplier Largan. In the call, a spokesperson from Largan said "some flagship specifications will be extended to other models" in the second half of 2024, presumably in reference to the upcoming iPhone Pro models. "Apple is Largan’s largest customer, and Largan is also Apple’s largest lens supplier," Kuo said. "Therefore, the quote likely refers to the fact that the new iPhone 16 Pro and Pro Max will have a tetraprism camera in 2H24 (while only the iPhone 15 Pro Max had this camera in 2H23).” The report goes on to say that the tetraprism camera for the iPhone 16 Pro series won't be all that different from the one in the iPhone 15 Pro Max. While the lack of an upgrade is disappointing, it's not necessarily a bad thing as these kinds of lenses are already top-of-the-line. They represent a major increase over prior models’ zoom capabilities, and they're capable of offering more depth while still fitting into super-slim smartphones. That being said, Apple does appear to be revamping the main camera and ultra-wide camera on the iPhone 16 Pro Max. Evidence continues to mount that both iPhone 16 Pro models will share the same 5x optical zoom camera. Earlier this week, DigitTimes in Asia (via 9to5Mac) reported that Apple is set to ramp up orders for tetraprism lenses as it expands their use in its upcoming iPhone series. Industry sources told the outlet that Largan and Genius Electronic Optical were tapped as the primary suppliers. Apple would be wise to streamline its Pro-level iPhones with the same camera setup; then all customers have to consider with their choice of a new iPhone is the size and price. Of course, this should all be taken with a grain of sand for now until we hear more from Apple. It's still a while yet before Apple's usual September time window for iPhone launches. In the meantime, be sure to check out all the rumors so far in our iPhone 16, iPhone 16 Pro and iPhone 16 Pro Max hubs.
OpenAI's internal AI details stolen in 2023 breach, NYT reports
July 4 (Reuters) - A hacker gained access to the internal messaging systems at OpenAI last year and stole details about the design of the company's artificial intelligence technologies, the New York Times reported, opens new tab on Thursday. The hacker lifted details from discussions in an online forum where employees talked about OpenAI's latest technologies, the report said, citing two people familiar with the incident. However, they did not get into the systems where OpenAI, the firm behind chatbot sensation ChatGPT, houses and builds its AI, the report added. OpenAI executives informed both employees at an all-hands meeting in April last year and the company's board about the breach, according to the report, but executives decided not to share the news publicly as no information about customers or partners had been stolen. OpenAI executives did not consider the incident a national security threat, believing the hacker was a private individual with no known ties to a foreign government, the report said. The San Francisco-based company did not inform the federal law enforcement agencies about the breach, it added. OpenAI in May said it had disrupted five covert influence operations that sought to use its AI models for "deceptive activity" across the internet, the latest to stir safety concerns about the potential misuse of the technology. The Biden administration was poised to open up a new front in its effort to safeguard the U.S. AI technology from China and Russia with preliminary plans to place guardrails around the most advanced AI Models including ChatGPT, Reuters earlier reported, citing sources.
Hedge fund Elliott challenges court verdict it lost against LME on nickel
LONDON, July 9 (Reuters) - U.S.-based hedge fund Elliott Associates on Tuesday urged a London court to overturn a verdict supporting the London Metal Exchange's (LME) cancellation of nickel trades partly because the exchange failed to disclose documents. The LME annulled $12 billion in nickel trades in March 2022 when prices shot to records above $100,000 a metric ton in a few hours of chaotic trade. Elliott and market maker Jane Street Global Trading brought a case demanding a combined $472 million in compensation, alleging at a trial in June last year that the 146-year-old exchange had acted unlawfully. London's High Court ruled last November that the LME had the right to cancel the trades because of exceptional circumstances, and was not obligated to consult market players prior to its decision. Lawyers for Elliott told London's Court of Appeal that the LME belatedly released documents in May detailing its "Kill Switch" and "Trade Halt" internal procedures. It also newly disclosed an internal report that Elliott said detailed potential conflicts of interest at the exchange. "It was troubling that one gets disclosure out of the blue in the Court of Appeal for the first time," Elliott lawyer Monica Carss-Frisk told the court. Jane Street Global did not appeal the ruling. "If we had had them (documents) in the proceedings before the divisional court, we may well have sought permission to cross examine." LME lawyers said the new documents were not relevant. "The disclosed documents do not affect the reasoning of the divisional court or the merits of the arguments on appeal," the exchange said in documents prepared for the appeal hearing. "Elliott's appeal is largely a repetition of the arguments which were advanced, and rightly rejected." The LME said it had both the power and a duty to unwind the trades because a record $20 billion in margin calls could have led to at least seven clearing members defaulting, systemic risk and a potential "death spiral". Elliott said the ruling diluted protection provided by the Human Rights Act and also wrongly concluded the LME had the power to cancel the trades.
Doctors visited the White House 8 times? White House: Biden did not receive treatment for Parkinson's disease
White House spokeswoman Karina Jean-Pierre denied a report in the U.S. media on the 8th that President Joseph Biden did not receive treatment for Parkinson's disease. Biden had the first televised debate of the 2024 presidential election with Republican opponent Donald Trump on June 27, and his poor performance on the spot triggered discussions about his physical condition. The New York Times reported that a doctor specializing in the treatment of Parkinson's disease had "visited" the White House eight times from August last year to March this year. Facing the media's questions about Biden's health, Jean-Pierre asked and answered himself at a regular White House press conference on the 8th: "Has the president received treatment for Parkinson's disease? No. Is he currently receiving treatment for Parkinson's disease? No, he is not. Is he taking medication for Parkinson's disease? No." Jean-Pierre said Biden had seen a neurologist three times, all related to his annual physical examination. She also took out the report issued by the doctor after Biden's most recent physical examination in February this year. The report said, "An extremely detailed neurological examination was once again reassuring" because no symptoms consistent with stroke, multiple sclerosis or Parkinson's disease were found. The doctor who went to the White House mentioned by the New York Times is Kevin Kanal, a neurology and movement disorder expert at the Walter Reed National Military Medical Center in Maryland and an authority on Parkinson's disease. Jean-Pierre suggested that the doctor might have come to treat military personnel on duty at the White House.
TSX futures rise ahead of Fed chair Powell's testimony
July 9 (Reuters) - Futures linked to Canada's main stock index rose on the back of metal prices on Tuesday, while investors awaited U.S. Federal Reserve Chair Jerome Powell's congressional testimony on monetary policy later in the day. The S&P/TSX 60 futures were up 0.25% by 06:28 a.m. ET (1028 GMT). The Toronto Stock Exchange's materials sector was set to re Oil futures , dipped as fears over supply disruption eased after Hurricane Beryl, which hit major refineries along with the U.S. Gulf Coast, caused minimal impact. Markets will be heavily focussed on Powell's two-day monetary policy testimony before the Senate Banking Committee, starting at 10 a.m. ET (1400 GMT), which can help investors gauge the Fed's rate-cut path. Following last week's softer jobs data, market participants are now pricing in a 77% chance of a rate cut by the U.S. central bank in September. The main macro event for the markets this week will be the U.S. consumer prices data due on Thursday, which can help assess the trajectory of inflation in the world' biggest economy. Wall Street futures were also up on Tuesday after the S&P 500 (.SPX), opens new tab and Nasdaq (.IXIC), opens new tab touched record closing highs in the previous session. In Canada, fears of the economy slipping into recession advanced after the latest data showed that the unemployment rate rose to a 29-month high in June. Traders are now pricing in a 65% chance of another cut by the Bank of Canada, which already trimmed interest rates last month. In corporate news, Cenovus Energy (CVE.TO), opens new tab said it is demobilizing some staff at its Sunrise oil sands project in northern Alberta as a precaution due to the evolving wildfire situation in the area.